Analyst Price Target is 20.00
▲ +90.48% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for SAB Biotherapeutics in the last 3 months. The average price target is 20.00, with a high forecast of 23.00 and a low forecast of 17.00. The average price target represents a 90.48% upside from the last price of 10.50.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in SAB Biotherapeutics.